Hand over computer screen

RG Schweiger

RG Schweiger

Research Group Leader LIR, Director of Institute for Human Genetics University Medical Center of the Johannes Gutenberg-University Mainz, Professor for Human Genetics


Monika Chongtham, PhD student

Julian Merz, PhD student

Marlon Wendelmuth, PhD student

PD Dr Jennifer Winter, Senior Scientist

Research group description

The aim is to find early molecular mechanisms that establish in the brain after chronic stress and which can then lead to a resilient behaviour. These early molecular mechanisms include epigenetic modification of chromatin, expression of non-coding RNAs, transcriptional changes in response to chronic stress but also changes in protein translation. We focus in particular on mechanisms caused by chronic defeat stress on the one hand and early life stress on the other. We use different mouse models, such as the Riboteq or the sun-GFP mouse, which help us to detect and characterize cell-specific changes. RNA sequencing, bi-sulfite sequencing, ATAC sequencing, and mass spectrometry are part of our methodological spectrum. In addition, epigenetic modulators and inhibitors of the mTOR kinase are used to influence resilient behavior. Furthermore, we are investigating in human cortical organoids the change of X inactivation during brain development as a possible modulator of behaviour.

Current research projects
  • Epigenetic modulation after chronic social defeat stress
  • Heritability of resilient behaviour
External cooperation partners
  • Prof. Dr Jochen Roeper, Institute for Neurophysiology, Goethe University Frankfurt
  • Prof. Dr Rainer Schneider, Institute of Biochemistry, University of Innsbruck, Austria
  • Dr Vera Kalscheuer, Max Planck Institute for Molecular Genetics, Berlin
  • Prof. Dr Benedikt Berninger, Centre for Developmental Neurobiology, King's College London, United Kingdom
  • German Research Foundation (DFG)
  • Boehringer Ingelheim Foundation
Key Publications

Arnoux I, Willam M, Griesche N, Krummeich J, Watari H, Offermann N, Weber S, Narayan Dey P, Chen C, Monteiro O, Buettner S, Meyer K, Bano D, Radyushkin K, Langston R, Lambert JJ, Wanker E, Methner A, Krauss S, Schweiger S, Stroh A (2018) Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease. eLife 7. pii: e38744. doi: 10.7554/eLife.38744.

>> Link to Pubmed

Deciphering Developmental Disorders Study (2017) Prevalence and architecture of de novo mutations in developmental disorders. Nature 542(7642):433-438.

>> Link to Pubmed

Schweiger S, Dorn S, Fuchs M, Köhler A, Matthes F, Müller EC, Wanker E, Schneider R, Krauß S (2014) The E3-ubiquitin ligase MID1 catalyzes ubiquitination and cleavage of Fu. J Biol Chem 289(46):31805-17. doi: 10.1074/jbc.M113.541219.

>> Link to Pubmed

Krauß S, Griesche N, Jastrzebska E, Chen C, Rutschow D, Achmüller C, Dorn S, Boesch SM, Lalowski M, Wanker E, Schneider R, Schweiger S (2013) Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex. Nature communications 4:1511 doi: 10.1038/ncomms2514.

>> Link to Pubmed

Liu E, Knutzen CA, Krauss S, Schweiger S, Chiang GG (2011) Control of mTORC1 signaling by the Opitz Syndrome protein, MID1. Proc Natl Acad Sci USA 108: 8680-868.

>> Link to Pubmed

Kickstein E, Krauß S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, Köhler A, Glossmann H, Schneider R, Sutherland C, Schweiger S (2010) The Biguanide Metformin acts on tau phosphorylation via mTOR/PP2A signaling. Proc Natl Acad Sci USA 107: 21830-21835.

>> Link to Pubmed